These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Histopathologically Validated Diagnostic Accuracy of PSMA-PET/CT in the Primary and Secondary Staging of Prostate Cancer and the Impact of PSMA-PET/CT on Clinical Management: A Systematic Review and Meta-analysis. Jeet V, Parkinson B, Song R, Sharma R, Hoyle M. Semin Nucl Med; 2023 Sep; 53(5):706-718. PubMed ID: 37005145 [Abstract] [Full Text] [Related]
65. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU. Eur Urol Oncol; 2022 Feb; 5(1):100-103. PubMed ID: 33602654 [Abstract] [Full Text] [Related]
75. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer. Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, Wetterauer U, Schultze-Seemann W, Meyer PT. Theranostics; 2017 Dec; 7(6):1770-1780. PubMed ID: 28529650 [Abstract] [Full Text] [Related]
76. 68Ga-PSMA PET/CT for the evaluation of metastasis in patients with prostate cancer: A systematic review and meta-analysis. Zhou J, Wu R, Wang W, Zhao Y, Liu X. Hell J Nucl Med; 2022 Dec; 25(3):297-311. PubMed ID: 36576728 [Abstract] [Full Text] [Related]